Heart failure (HF) is a clinical syndrome caused by structural or functional cardiac abnormalities, characterized by symptoms like shortness of breath and wheezing due to fluid accumulation in the lungs. Acute lung injury (ALI) is an inflammation-driven condition that increases lung permeability, leading to respiratory failure. ALI can coexist with HF, and the underlying lung injury involves endothelial dysfunction and increased vascular permeability. Acute respiratory distress syndrome (ARDS) is an advanced form of ALI, defined by severe respiratory failure, hypoxia, and bilateral lung opacities. The pathophysiology of both HF and ALI/ARDS involves complex interactions between mechanical injury, inflammatory responses, and oxidative stress, with disruption of the alveolar-capillary barrier. No reliable biomarkers currently distinguish between pulmonary oedema from HF and ALI/ARDS, but surfactant proteins like SP-B may hold potential for diagnosis. Understanding these mechanisms is crucial for developing therapeutic strategies targeting both conditions.

Heart Failure and Acute Lung Injury

Spampinato, Michele Domenico
Primo
;
2025

Abstract

Heart failure (HF) is a clinical syndrome caused by structural or functional cardiac abnormalities, characterized by symptoms like shortness of breath and wheezing due to fluid accumulation in the lungs. Acute lung injury (ALI) is an inflammation-driven condition that increases lung permeability, leading to respiratory failure. ALI can coexist with HF, and the underlying lung injury involves endothelial dysfunction and increased vascular permeability. Acute respiratory distress syndrome (ARDS) is an advanced form of ALI, defined by severe respiratory failure, hypoxia, and bilateral lung opacities. The pathophysiology of both HF and ALI/ARDS involves complex interactions between mechanical injury, inflammatory responses, and oxidative stress, with disruption of the alveolar-capillary barrier. No reliable biomarkers currently distinguish between pulmonary oedema from HF and ALI/ARDS, but surfactant proteins like SP-B may hold potential for diagnosis. Understanding these mechanisms is crucial for developing therapeutic strategies targeting both conditions.
2025
9783031974489
9783031974496
File in questo prodotto:
File Dimensione Formato  
Noninvasive Ventilatory Support in Cardiac Disorders.pdf

solo gestori archivio

Descrizione: Full text editoriale
Tipologia: Full text (versione editoriale)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 657.81 kB
Formato Adobe PDF
657.81 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2604675
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact